Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine plus carboplatin vs physician’s choice in platinum-resistant ovarian cancer
2017-004099-71Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Nov 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of decitabine and carboplatin in ovarian cancer (2 arms), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Progression-free survival. Started Nov 2020; status: completed.
02
Drugs
decitabinecarboplatin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2017-004099-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004099-71.